Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks-- and the track records of the firms behind them -- so individuals can make better investing decisions.
In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 140,000 members, many of whom demonstrate better investing insight than published analysts do.
After being pummeled down to a two-star rank earlier this summer, enough top-performing CAPS members turned bullish on Cytori Therapeutics
Many CAPS members are bullish on the future of stem-cell technologies and expect Cytori's products to become more widely accepted and applied going forward. Large drugmakers like Pfizer
In recent quarters, the company has been lowering expenses, narrowing its losses, and boosting its third-party revenue as it ramps up its Celution and StemSource products around the world. It recognized $7.3 million in development revenue from its Olympus partnership in the second quarter, sending its year-over-year total revenue growth into the stratosphere, and an expanded deal with General Electric's
The company expects annual revenue growth, but because of the sales cycle of its products, this can fluctuate dramatically, setting up the stock volatility that investors in Geron
Do you think Cytori Therapeutics deserves its star bump? Add your thoughts in the comments box below, or head over to CAPS to rate it yourself and check out all the information and opinions the community offers. CAPS is totally free.
The Motley Fool Rule Breakers service looks for companies set to outpace the market with new, innovative technologies. To see all the stocks that David Gardner and his team believe will do this, take a free 30-day trial.
Fool contributor Dave Mock recently upgraded his odds at poker by controlling his nail-biting habit. He owns shares of Johnson & Johnson and Pfizer in dividend reinvestment plans. Pfizer is a Motley Fool Inside Value recommendation. Johnson & Johnson is a Motley Fool Income Investor selection. The Fool's disclosure policy goes all in on low pairs.